Bank of America: Closer Look at Ariad Pharmaceuticals' Inhibitor Landscape

In a research report published today by Bank of America, investors are beginning to focus on Ariad Pharmaceuticals'

early-stage oncology drug, AP-26113. According to Bank of America, “This report takes a broad look at the ALK inhibitor development landscape. We have several preliminary conclusions: (1) the future second generation ALK inhibitor market is up for grabs, as four companies are in early stage development and lots more could move into clinic over the next 1-2 yrs (2) ARIA is running the most intelligently designed clinical study in our view, and is well positioned to move into Phase 3 in 2013 pending data (3) ARIA and Novartis could be the most promising early stage candidates if pK/safety offer no surprises.” Bank of America maintains its Neutral rating and $16 PT on Ariad Pharmaceuticals, which closed yesterday at $14.56.